{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T06:37:55Z","timestamp":1772087875925,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Purposes<\/jats:title>\n                    <jats:p>To investigate the efficacy and safety of subretinal balanced salt solution (BSS) injections for macular edema secondary to retinal vein occlusion (RVO-ME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 19 eyes of 19 patients characterized by Retinal vein occlusion (RVO) diagnosed using retinal angiography and persistent or recurrent edema on optical coherence tomography after at least three standard-dose anti-vascular endothelial growth factor (VEGF) treatments. The operation group received pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling and subretinal injection of BSS. The injection group continued to receive intravitreal injection of anti-VEGF drugs. The results of visual acuity, retinal morphology, and recurrence were analyzed and compared between the two groups after treatment. Statistical comparisons were adjusted for baseline imbalances using analysis of covariance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After adjustment for baseline best corrected visual acuity (BCVA) and prior injection number, the difference in final BCVA between the surgery and injection groups was not statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.081). However, the surgery group demonstrated a statistically significant reduction in final Central macular thickness after adjustment (adjusted mean: 222.67 \u03bcm vs. 270.60 \u03bcm,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.048). The surgery group also showed a strong trend toward a lower recurrence rate (40.0% vs. 88.9%,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.051) and a longer median time to recurrence (10.0 vs. 4.0 months), though the latter was not statistically significant (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      = 0.503). No serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This preliminary study suggests that PPV combine with ILM peeling and subretinal BSS injection was feasible and associated with significant anatomical improvement in refractory RVO-ME. The procedure has shown potential in controlling edema and reducing recurrence. While visual outcomes were comparable to anti-VEGF after adjustment, the anatomical benefit warrants further investigation in prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1701735","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:15Z","timestamp":1772083755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Subretinal injection of balanced salt solution for macular edema secondary to retinal vein occlusion"],"prefix":"10.3389","volume":"13","author":[{"given":"Yue","family":"Pan","sequence":"first","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zetong","family":"Nie","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxing","family":"Chi","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinning","family":"Xie","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqi","family":"An","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaorong","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbo","family":"Li","sequence":"additional","affiliation":[{"name":"Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojie","family":"Hu","sequence":"additional","affiliation":[{"name":"NHC Key Laboratory of Hormones and Development, Tianjin Key Laboratory of Metabolic Diseases, Chu Hsien-I Memorial Hospital and Tianjin Institute of Endocrinology, Tianjin Medical University","place":["Tianjin, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ophtha.2009.07.017","article-title":"The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia.","volume":"117","author":"Rogers","year":"2010","journal-title":"Ophthalmology."},{"key":"B2","doi-asserted-by":"publisher","first-page":"432685","DOI":"10.1155\/2014\/432685","article-title":"The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases.","volume":"2014","author":"Ascaso","year":"2014","journal-title":"Mediators Inflamm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.ophtha.2017.06.027","article-title":"Sustained benefits of ranibizumab with or without laser in branch retinal vein occlusion: 24-month results of the BRIGHTER study.","volume":"124","author":"Tadayoni","year":"2017","journal-title":"Ophthalmology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1159\/000487547","article-title":"Dexamethasone intravitreal implant for early treatment and retreatment of macular edema related to branch retinal vein occlusion: the multicenter COBALT study.","volume":"240","author":"Yoon","year":"2018","journal-title":"Ophthalmologica."},{"key":"B5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00417-019-04577-8","article-title":"Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.","volume":"258","author":"Giuffr\u00e8","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/08820538.2023.2249527","article-title":"Intravitreal injection of anti-vascular endothelial growth factors combined with corticosteroids for the treatment of macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis.","volume":"39","author":"Namvar","year":"2024","journal-title":"Semin Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8460","DOI":"10.1038\/s41598-021-88149-z","article-title":"Cystotomy with or without fibrinogen clot removal for refractory cystoid macular edema secondary to branch retinal vein occlusion.","volume":"11","author":"Yamada","year":"2021","journal-title":"Sci Rep."},{"key":"B8","doi-asserted-by":"publisher","first-page":"951666","DOI":"10.3389\/fphar.2022.951666","article-title":"Efficacy of single-dose intravitreal dexamethasone implantation for retinal vein occlusion patients with refractory macular edema: a systematic review and meta-analysis.","volume":"13","author":"Yuan","year":"2022","journal-title":"Front Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e29334","DOI":"10.1016\/j.heliyon.2024.e29334","article-title":"Multimodal deep transfer learning to predict retinal vein occlusion macular edema recurrence after anti-VEGF therapy.","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s00417-020-04756-y","article-title":"Removal of foveal hard exudates by subretinal balanced salt solution injection using 38-gauge needle in diabetic patients.","volume":"258","author":"Kumagai","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1097\/IAE.0000000000003879","article-title":"Displacement of submacular hemorrhage with vitrectomy combined with subretinal balanced salt solution and air.","volume":"43","author":"Handa","year":"2023","journal-title":"Retina."},{"key":"B12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2147\/IMCRJ.S244166","article-title":"Displacement of retained subretinal perfluorocarbon liquid through therapeutic retinal detachment induced by balanced salt solution injection.","volume":"13","author":"Saab","year":"2020","journal-title":"Int Med Case Rep J."},{"key":"B13","article-title":"Internal limiting peeling in conjunction with subretinal injection of a balanced salt solution in the macular region to treat refractory diabetic macular edema.","author":"Mao","year":"2024","journal-title":"Altern Ther Health Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2147\/OPTH.S195600","article-title":"Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion.","volume":"13","author":"Kumagai","year":"2019","journal-title":"Clin Ophthalmol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/OPTH.S203212","article-title":"Vitrectomy for macular edema due to retinal vein occlusion.","volume":"13","author":"Kumagai","year":"2019","journal-title":"Clin Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/IAE.0b013e3181bced68","article-title":"Long-term effects of vitrectomy and internal limiting membrane peeling for macular edema secondary to central retinal vein occlusion and hemiretinal vein occlusion.","volume":"30","author":"Park","year":"2010","journal-title":"Retina Phila Pa."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/OPTH.S23164","article-title":"Pars plana vitrectomy and internal limiting membrane peeling for macular edema secondary to retinal vein occlusion.","volume":"5","author":"Baharivand","year":"2011","journal-title":"Clin Ophthalmol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2019.03.029","article-title":"Loss of peak vision in retinal vein occlusion patients treated for macular edema.","volume":"205","author":"Iftikhar","year":"2019","journal-title":"Am J Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.ophtha.2016.01.011","article-title":"Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study.","volume":"123","author":"Larsen","year":"2016","journal-title":"Ophthalmology."},{"key":"B21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2147\/OPTH.S123419","article-title":"Five-year outcomes of pars plana vitrectomy for macular edema associated with branch retinal vein occlusion.","volume":"11","author":"Nishida","year":"2017","journal-title":"Clin Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000004282","article-title":"Application of subretinal balanced salt solution injection: a novel technique in treating severe idiopathic epiretinal membrane.","author":"Luan","year":"2022","journal-title":"Retina."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.oret.2025.05.025","article-title":"Treatment patterns and long-term outcomes with anti-VEGF therapy for retinal vein occlusion: an analysis of the vestrum database.","volume":"9","author":"Ip","year":"2025","journal-title":"Ophthalmol Retina."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6288582","DOI":"10.1155\/2022\/6288582","article-title":"Real-life efficacy of bevacizumab treatment for macular edema secondary to central retinal vein occlusion according to pro re nata or treat-and-extend regimen in eyes with or without epiretinal membrane.","volume":"2022","author":"Hamam","year":"2022","journal-title":"J Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.ophtha.2023.05.023","article-title":"SCORE2 investigator group. SCORE2 report 24: nonlinear relationship of retinal thickness and visual acuity in central retinal and hemiretinal vein occlusion.","volume":"130","author":"Scott","year":"2023","journal-title":"Ophthalmology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1701735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:29:15Z","timestamp":1772083755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1701735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":25,"alternative-id":["10.3389\/fmed.2026.1701735"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1701735","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"article-number":"1701735"}}